

PRESS RELEASE

MetrioPharm AG Announces Change In Management Team

- [Sven Zimmermann to leave MetrioPharm AG as of March 31, 2021](#)

Zurich, March 05, 2021. MetrioPharm AG announces that Sven Zimmermann will leave the company as of March 31, 2021. Sven Zimmermann was the CFO of MetrioPharm AG since August 2019. He is leaving the company at his own request to pursue new professional goals. His current responsibilities in the company will be taken over by the Management Board.

Dr. Wolfgang Brysch, CEO of MetrioPharm comments on the change in management: "We were able to advance MetrioPharm very successfully together with Sven Zimmermann since 2019. We all regret very much - both personally and professionally - that he is leaving our team but wish him every success in his new tasks."

About MetrioPharm AG

MetrioPharm AG is a pharmaceutical development company focusing on drugs for chronic inflammatory diseases such as psoriasis, arthritis, and multiple sclerosis. Such chronic diseases pose the greatest individual health risk. The goal of MetrioPharm AG is to make the therapy of chronic inflammatory diseases more effective and more tolerable. We hope to achieve a healthspan expansion for patients: We want to stop the progression of chronic inflammatory diseases as early as possible and significantly prolong the healthy lifespan of millions of people.

MetrioPharm was founded in 2007 with headquarters in Zurich. The company has its R&D activities in Berlin.

About MP1032

MP1032 is the lead compound of a class of proprietary immune modulators developed by MetrioPharm AG. MP1032 is believed to modulate the oxidative stress-mediated activation state of macrophages and downregulate the M1 state. In contrast to other immune-modulating and disease-modifying drugs, MP1032 does not impact T-cells and preferentially affects macrophages at the sites of inflammation. MP1032 has shown anti-inflammatory activity in animal models of disease and a favorable toxicology profile in pre-clinical studies.

For the first Phase II study with MP1032, the indication psoriasis was selected because this immune-induced inflammatory disease is regarded as a so-called »door-opener indication«. Successes in the treatment of psoriasis have already led to first indications of promise for use in other chronic inflammatory diseases, such as arthritis and multiple sclerosis.

PRESS RELEASE

In a preclinical study published in the International Journal of Molecular Science, MP1032 was shown to exert both potent immunomodulatory effects on ROS and SARS-CoV-2-specific antiviral properties. MetrioPharm's lead compound thus has the potential to both slow viral spread in the body and alleviate Covid-19 symptoms. A Phase II clinical trial in Covid-19 patients is being prepared for the first half of 2021.

Forward-looking statements

This press release contains forward-looking statements that involve risks and uncertainties and are consistent with MetrioPharm AG's assessment as of the date of this release. Such forward-looking statements are neither promises nor guarantees, but are subject to numerous risks and uncertainties, many of which are beyond MetrioPharm AG's control, that could cause actual results to differ materially from those contemplated in these forward-looking statements. MetrioPharm does not assume any obligation to update forward-looking statements with respect to changed expectations or new events, conditions or circumstances on which these statements are based. A liability or guarantee and, if applicable, claims for topicality, correctness and completeness of these data and information are excluded and cannot be derived either explicitly or impliedly.

Your Contact



Lia Petridou
Corporate Communications &
Press Relations

T +49 (0) 30 33 84 395 53
F +49 (0) 30 33 84 395 99
E presse@metriopharm.com
W www.metriopharm.com

PRESS RELEASE